In September, the U.S. Food and Drug Administration announced that, in order to reduce the risk of patients acquiring NSF, it would require changes in the labeling of gadolinium-based contrast agents.
As of December, product labels have been updated for the following gadolinium-based contrast agents:
- Ablavar
- Eovist
- Magnevist
- Multihance
- Omniscan
- Optimark
- Prohance
The changes to the labels should help medical professionals use the drugs properly and help them effectively screen patients with kidney problems who are at risk for developing NSF.
If you or someone you know has developed nephrogenic systemic fibrosis or a similar condition after being exposed to gadolinium-based contrast agents during an MRI scan, the
gadolinium attorneys of Williams Kherkher can help. To learn more, contact our offices today at 800-761-3187.